title: Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
abstract: OBJECTIVE
  Weekly dosing of paclitaxel has been demonstrated to be a well-tolerated, feasible and effective administration schedule. In this study, we evaluated the efficacy and safety of weekly paclitaxel in Japanese women with advanced or metastatic breast cancer.
  
  
  METHODS
  Seventy-four patients were enrolled in the study. Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week. Administration was continued for 3 weeks followed by a 1 week rest. A short premedication, consisting of dexamethasone 10 mg, ranitidine 50 mg and diphenylhydramine 50 mg, was given prior to each dose of paclitaxel. Eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0, 1 or 2 and adequate hematological, hepatic and renal function.
  
  
  RESULTS
  Of 74 patients treated and evaluable for toxicities, 70 were evaluable for response. The mean age was 57.7 years. Forty-nine patients (66.2%) had received prior anthracyclines for metastatic diseases. The overall response rate among 74 patients was 40.5%, including 4.1% complete responses and 36.5% partial responses. The median follow-up time was 481 days (range, 24-903 days). The median time to progression was 4.8 months and median overall survival was 15.8 months. The majority of patients tolerated the treatment very well. Although alopecia was observed in most of the patients (93.2%), grade 3 or 4 neutropenia was 10.8% and grade 2 or 3 peripheral neuropathy was 13.5%.
  
  
  CONCLUSIONS
  Weekly paclitaxel as a 1 h infusion was active and generally well tolerated in previously treated patients. Further study of weekly paclitaxel in combination therapy is warranted.
authors.affiliation: Department of Surgery I, National Defense Medical College, Tokorozawa, Saitama, Japan. sato-k-a@mtg.biglobe.ne.jp
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Sato
authors.forename: Kenichi
authors.initials: K
authors.lastname: Inoue
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Saito
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kai
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Mihara
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Okubo
authors.forename: Junichi
authors.initials: J
authors.lastname: Koh
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Mochizuki
authors.forename: Toshio
authors.initials: T
authors.lastname: Tabei
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000932:Antiemetics / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage; D004155:Diphenhydramine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011899:Ranitidine / Q000008:administration & dosage; D012983:Soft Tissue Neoplasms / Q000556:secondary; D014840:Vomiting, Anticipatory / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000972:Antineoplastic Agents, Phytogenic; D003907:Dexamethasone; D011899:Ranitidine; D004155:Diphenhydramine; D017239:Paclitaxel